The frequency of AESIs experienced by patients receiving UPA 15 mg through week 12 was generally similar compared with patients receiving PBO, except for serious infection, HZ, hepatic disorder, neutropenia, and CPK elevation, which were reported in a higher proportion of patients receiving UPA 15 mg. Here, PIK3C2A is linked to liver disorder.